Veracyte (VCYT) Stock Price & Analysis
Score
AI Analysis
SnapshotVeracyte mixes growth with a still-reasonable multiple — Growth 71/100 with P/E 15.1. Under the hood: P/E 15.1, plus revenue compounding ~20% annually over recent years. Street targets still imply ~123% upside.
Price History
Price: —
Fair value: —
—
P/E (TTM): —
Net Income (TTM): —
Score: —
—
Score Breakdown
Market percentile scores loading…
Value
Growth
Quality
Financial Summary
Veracyte, Inc. (VCYT) last printed $24.33. Equity value is $1.96B. Trailing earnings multiple 15.44. The revenue row is reported history. Targets and ratings are on the forecast page.
Financials
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| $65.08M | $71.95M | $92.01M | $120.37M | $117.48M | $219.51M | $296.54M | $361.05M | $445.76M | $517.14M |
About
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.